Regeneron Pharmaceutical (REGN) 393.40 $REGN Biotech

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Regeneron Pharmaceutical (REGN) 393.40 $REGN

Biotech Stock Roundup: Gilead in Patent Infringement Lawsuit, Enbrel Biosimilar Approved
Arpita Dutt - Zacks Investment Research - Thu Sep 01, 9:54AM CDT
The overall healthcare sector was under pressure with focus going back to the pricing policies of pharma and biotech companies.
GILD: 77.42 (-0.96), ALXN: 125.63 (-0.23), MYL: 41.92 (-0.44), AMGN: 170.13 (+0.07), ARIA: 10.19 (-0.15), RIGL: 3.45 (+0.08), REGN: 393.40 (+0.85)

Regeneron Announces Upcoming 2016 Investor Conference Presentations
PR Newswire - Thu Sep 01, 8:30AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast a management presentation at the following investor conferences:
REGN: 393.40 (+0.85)

The Medicines Co. Offers Update on Dyslipidemia Programs
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 9:13AM CDT
The Medicines Company (MDCO) provided an update on its dyslipidemia programs - MDCO-216 and PCSK9si (PCSK9 synthesis inhibitor).
MDCO: 38.97 (-0.20), AMGN: 170.13 (+0.07), SNY: 38.41 (-0.06), REGN: 393.40 (+0.85)

Regeneron/Sanofi Present Positive Phase III Praluent Data
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:33AM CDT
Regeneron Pharmaceuticals (REGN) and Sanofi presented positive phase III data on Praluent in patients who underwent LDL apheresis therapy.
ANIP: 61.42 (+1.68), AMGN: 170.13 (+0.07), SNY: 38.41 (-0.06), REGN: 393.40 (+0.85)

Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016
PR Newswire - Mon Aug 29, 1:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced detailed positive results from ODYSSEY ESCAPE, a Phase 3 trial which evaluated Praluent® (alirocumab) Injection in patients with an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia (HeFH) who require regular weekly or bi-weekly apheresis treatment. The trial demonstrated that adding Praluent to existing therapy reduced LDL cholesterol by approximately 50 percent from baseline (compared to 2 percent increase for placebo). Praluent significantly reduced the need for apheresis treatment by 75 percent compared to placebo (p less than 0.0001), the primary endpoint of the study. Results will be presented today at a Hot Line session at the ESC Congress 2016 in Rome, Italy.
SAN: 4.52 (+0.04), SNY: 38.41 (-0.06), REGN: 393.40 (+0.85)

Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Arpita Dutt - Zacks Investment Research - Wed Aug 24, 1:09PM CDT
Acquisitions are back in focus in the biotech sector with Medivation (MDVN) agreeing to be acquired by Pfizer for $14 billion.
MDVN: 80.93 (+0.37), BIIB: 306.03 (+0.40), PTLA: 20.86 (+0.50), CLVS: 23.59 (-1.18), GILD: 77.42 (-0.96), ALXN: 125.63 (-0.23), REGN: 393.40 (+0.85)

Regeneron Stock Up on BARDA Deal for MERS Antibodies
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 8:48AM CDT
Regeneron Pharmaceuticals (REGN) has signed up with BARDA for the development of treatments targeting MERS viru
ANIP: 61.42 (+1.68), GERN: 2.73 (+0.04), SNY: 38.41 (-0.06), REGN: 393.40 (+0.85)

Medivation and Syngenta climb; Viacom, Marathon Oil fall
AP - Mon Aug 22, 3:43PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Monday:
MDVN: 80.93 (+0.37), VIA: 44.42 (-0.77), MUR: 26.39 (-0.33), SYT: 87.68 (+0.43), PFE: 34.68 (-0.12), ODP: 3.62 (-0.06), MRO: 15.11 (+0.09), ISIL: 20.25 (+0.51), VIAB: 39.77 (-0.57), REGN: 393.40 (+0.85)

After Yesterday's Rally of 4.34% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 22, 12:10PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $405.10 to a high of $422.30. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high of $415.82 on volume of 508,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 393.40 (+0.85)

Regeneron Announces Agreement with BARDA for the Manufacturing and Testing of New Antibodies Against MERS Virus
PR Newswire - Mon Aug 22, 7:30AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced an agreement with the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) to manufacture and study two antibody therapies for the potential prevention and treatment of Middle East Respiratory Syndrome (MERS). Regeneron has previously published details on how its proprietary VelociGene® and VelocImmune® technologies enabled the rapid identification and preclinical validation of these antibody candidates.
REGN: 393.40 (+0.85)

J&J (JNJ) Remicade Patent Invalid, Pfizer to Launch Inflectra?
Arpita Dutt - Zacks Investment Research - Thu Aug 18, 6:39AM CDT
With the court finding J&J's (JNJ) Remicade patent invalid, will Pfizer go for an "at-risk" launch?
JNJ: 119.08 (-0.26), PFE: 34.68 (-0.12), REGN: 393.40 (+0.85)

The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 8:30AM CDT
The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen
BIIB: 306.03 (+0.40), BMRN: 95.19 (+1.30), AMGN: 170.13 (+0.07), ABBV: 64.03 (-0.07), REGN: 393.40 (+0.85)

Biotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat
Arpita Dutt - Zacks Investment Research - Thu Aug 11, 4:30PM CDT
Earnings remained in focus with several companies including Regeneron (REGN) reporting second quarter results.
MDVN: 80.93 (+0.37), BIIB: 306.03 (+0.40), BMRN: 95.19 (+1.30), AMGN: 170.13 (+0.07), ABBV: 64.03 (-0.07), MNTA: 12.15 (+0.13), REGN: 393.40 (+0.85)

Adverum (ADVM) Reports Narrower-than-Expected Q2 Loss
Zacks Equity Research - Zacks Investment Research - Thu Aug 11, 8:31AM CDT
Adverum (ADVM) reported a narrower-than-expected loss in the second quarter. The company also decided to discontinue the development of lead candidate.
ADVM: 3.55 (-0.03), CORT: 5.35 (+0.02), PCRX: 40.37 (+0.74), REGN: 393.40 (+0.85)

What's in Store for Adverum (ADVM) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:47AM CDT
Adverum Biotechnologies, Inc. (ADVM) is expected to report second-quarter 2016 results on Aug 11.
ADVM: 3.55 (-0.03), ADHD: 4.74 (-0.18), AVXS: 34.53 (-0.81), REGN: 393.40 (+0.85)

Uptrend Call Working As Regeneron Pharmaceuticals Stock Rises 15.7% (REGN)
Comtex SmarTrend(R) - Thu Aug 04, 1:51PM CDT
SmarTrend identified an Uptrend for Regeneron Pharmaceuticals (NASDAQ:REGN) on July 6th, 2016 at $364.02. In approximately 4 weeks, Regeneron Pharmaceuticals has returned 15.71% as of today's recent price of $421.23.
REGN: 393.40 (+0.85)

Regeneron (REGN) Tops Q2 Earnings, Keeps '16 Eylea View
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 10:33AM CDT
Regeneron Pharmaceuticals (REGN) reported better-than-expected second-quarter 2016 earnings of $2.10 per share.
ANIP: 61.42 (+1.68), SNY: 38.41 (-0.06), REGN: 393.40 (+0.85)

Regeneron (REGN) Beats on Q2 Earnings, Retains Eylea View
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 7:22AM CDT
Regeneron???s (REGN) second-quarter 2016 earnings surpassed expectations.
REGN: 393.40 (+0.85)

Regeneron Reports Second Quarter 2016 Financial and Operating Results
PR Newswire - Thu Aug 04, 5:30AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2016 and provided a business update.
REGN: 393.40 (+0.85)

5 Drug Stocks to Watch for Earnings on Aug 4: BMRN & More
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 8:36AM CDT
How will drug stocks like BMRN, TEVA, REGN and others, scheduled to report on Aug 4, fare this earnings season?
ACAD: 32.10 (-0.03), BMRN: 95.19 (+1.30), ALNY: 69.02 (-0.83), TEVA: 50.90 (+0.51), REGN: 393.40 (+0.85)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 124

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 7

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 415

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 324

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 136

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 77

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 42

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 44

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 416

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 258

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation into Inspire Medical Systems: What Investors Need to Know

Updated Category News Views 166

Investigation of Inspire Medical Systems and Shareholder Rights Faruqi & Faruqi, LLP, a prominent player in the field of securities law, is taking proactive steps to investigate potential claims regarding Inspire Medical Systems, Inc. This company has garnered attention recently due to its significant developments and ongoing operations. Investors who have experienced...

Continue Reading
Ecopro BM Faces Downgrade Amidst Battery Industry Challenges

Updated Category News Views 71

Market Response to Ecopro BM's Stock Downgrade Recently, Ecopro BM Co Ltd (247540:KS) faced a significant shift in its market perception as Nomura/Instinet downgraded the company's stock rating from Buy to Neutral. This adjustment comes with a newly revised price target focused on KRW240,000, a notable decrease from the previous KRW290,000. The decision is primarily...

Continue Reading
Exploring the Current State of Sea's Options Trading Landscape

Updated Category News Views 163

Exploring the Current State of Sea's Options Trading Landscape Recent market movements surrounding Sea (NYSE: SE) have sparked considerable interest among investors and traders alike. A comprehensive analysis of the options trading history for Sea reveals notable bearish activity. In our investigation, we identified 16 unusual trades that reflect a cautious outlook among...

Continue Reading
Empowering Women in Whiskey: The Rise of Lythgoe Bourbon

Updated Category News Views 94

Celebrating Women in the Whiskey Industry with Lythgoe Bourbon In a male-dominated field, one entrepreneur is making waves by honoring women in whiskey. The story of Lythgoe Bourbon begins with Dina Coker, who recognized a remarkable trend in the bourbon market. Despite the traditional narrative focused on male brands and locations in Kentucky, women are a significant...

Continue Reading
Waste Connections Declares Quarterly Cash Dividend for Investors

Updated Category News Views 110

Waste Connections Announces Regular Quarterly Cash Dividend Waste Connections, Inc. (TSX/NYSE: WCN) is making strides in providing returns for its shareholders by declaring a regular quarterly cash dividend of $0.315 U.S. per common share. This decision was made by the Company's Board of Directors and reflects their commitment to offering consistent shareholder value. The...

Continue Reading